PMLT21062 / APEC1621M / Mullen
Basic Study Information
Purpose:
This phase II pediatric MATCH trial studies how well tipifarnib works in treating
patients with solid tumors that have recurred or spread to other places in the body
(advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in
the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific
genetic changes in a gene called HRAS and may reduce tumor size.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Craig Mullen
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search